Inventor · disambiguated record
Ingrid Wertz
Also filed as: WERTZ INGRID · WERTZ INGRID E
5 granted patents·7 pending applications·9 citations·filing 2014–2025
72Inventor score
Top patents by PatentIndex Score
12 records- 0190US10898570B2Combination therapy with an anti-HER2 antibody-drug conjugate and a Bcl-2 inhibitorGENENTECH INC·Filed 2017·Granted Jan 26, 2021·3 cites·6 claims
- 0289US2025367287A1Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitorGENENTECH INC·Filed 2025·Application pending·0 cites
- 0388US2025121058A1Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitorGENENTECH INC·Filed 2024·Application pending·0 cites
- 0486US2024277838A1Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitorGENENTECH INC·Filed 2024·Application pending·0 cites
- 0584US12440706B2Conjugated chemical inducers of degradation and methods of useGENENTECH INC·Filed 2021·Granted Oct 14, 2025·1 cites·17 claims
- 0679US11666581B2PROTAC antibody conjugates and methods of useGENENTECH INC·Filed 2018·Granted Jun 6, 2023·2 cites·22 claims
- 0777US10766903B2Piperidine derivatives as inhibitors of ubiquitin specific protease 7ALMAC DISCOVERY LTD·Filed 2017·Granted Sep 8, 2020·3 cites·22 claims
- 0873US2021213130A1Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitorGENENTECH INC·Filed 2020·Application pending·0 cites
- 0969US2023330102A1Protac antibody conjugates and methods of useGENENTECH INC·Filed 2023·Application pending·0 cites
- 1045US2016136295A1Biomarkers for treatment with anti-tubulin chemotherapeutic compoundsGENENTECH INC·Filed 2014·Application pending·0 cites
- 1134US2016375033A1Methods of treatment with taselisibGENENTECH INC·Filed 2016·Application pending·0 cites
- 1227US9573899B2USP7 inhibitor compounds and methods of useGENENTECH INC·Filed 2016·Granted Feb 21, 2017·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when Ingrid Wertz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →